212 related articles for article (PubMed ID: 26868508)
1. RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease.
Gilham D; Wasiak S; Tsujikawa LM; Halliday C; Norek K; Patel RG; Kulikowski E; Johansson J; Sweeney M; Wong NC; Gordon A; McLure K; Young P
Atherosclerosis; 2016 Apr; 247():48-57. PubMed ID: 26868508
[TBL] [Abstract][Full Text] [Related]
2. RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo.
Bailey D; Jahagirdar R; Gordon A; Hafiane A; Campbell S; Chatur S; Wagner GS; Hansen HC; Chiacchia FS; Johansson J; Krimbou L; Wong NC; Genest J
J Am Coll Cardiol; 2010 Jun; 55(23):2580-9. PubMed ID: 20513599
[TBL] [Abstract][Full Text] [Related]
3. A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice.
Jahagirdar R; Zhang H; Azhar S; Tobin J; Attwell S; Yu R; Wu J; McLure KG; Hansen HC; Wagner GS; Young PR; Srivastava RA; Wong NC; Johansson J
Atherosclerosis; 2014 Sep; 236(1):91-100. PubMed ID: 25016363
[TBL] [Abstract][Full Text] [Related]
4. Data on gene and protein expression changes induced by apabetalone (RVX-208) in ex vivo treated human whole blood and primary hepatocytes.
Wasiak S; Gilham D; Tsujikawa LM; Halliday C; Norek K; Patel RG; McLure KG; Young PR; Gordon A; Kulikowski E; Johansson J; Sweeney M; Wong NC
Data Brief; 2016 Sep; 8():1280-8. PubMed ID: 27570805
[TBL] [Abstract][Full Text] [Related]
5. RVX 208: A novel BET protein inhibitor, role as an inducer of apo A-I/HDL and beyond.
Ghosh GC; Bhadra R; Ghosh RK; Banerjee K; Gupta A
Cardiovasc Ther; 2017 Aug; 35(4):. PubMed ID: 28423226
[TBL] [Abstract][Full Text] [Related]
6. Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial.
Nicholls SJ; Puri R; Wolski K; Ballantyne CM; Barter PJ; Brewer HB; Kastelein JJ; Hu B; Uno K; Kataoka Y; Herrman JP; Merkely B; Borgman M; Nissen SE
Am J Cardiovasc Drugs; 2016 Feb; 16(1):55-65. PubMed ID: 26385396
[TBL] [Abstract][Full Text] [Related]
7. ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies.
Nicholls SJ; Gordon A; Johannson J; Ballantyne CM; Barter PJ; Brewer HB; Kastelein JJ; Wong NC; Borgman MR; Nissen SE
Cardiovasc Drugs Ther; 2012 Apr; 26(2):181-7. PubMed ID: 22349989
[TBL] [Abstract][Full Text] [Related]
8. RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist.
McLure KG; Gesner EM; Tsujikawa L; Kharenko OA; Attwell S; Campeau E; Wasiak S; Stein A; White A; Fontano E; Suto RK; Wong NC; Wagner GS; Hansen HC; Young PR
PLoS One; 2013; 8(12):e83190. PubMed ID: 24391744
[TBL] [Abstract][Full Text] [Related]
9. Effects of the BET-inhibitor, RVX-208 on the HDL lipidome and glucose metabolism in individuals with prediabetes: A randomized controlled trial.
Siebel AL; Trinh SK; Formosa MF; Mundra PA; Natoli AK; Reddy-Luthmoodoo M; Huynh K; Khan AA; Carey AL; van Hall G; Cobelli C; Dalla-Man C; Otvos JD; Rye KA; Johansson J; Gordon A; Wong NC; Sviridov D; Barter P; Duffy SJ; Meikle PJ; Kingwell BA
Metabolism; 2016 Jun; 65(6):904-14. PubMed ID: 27173469
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208).
Wasiak S; Gilham D; Tsujikawa LM; Halliday C; Calosing C; Jahagirdar R; Johansson J; Sweeney M; Wong NC; Kulikowski E
J Cardiovasc Transl Res; 2017 Aug; 10(4):337-347. PubMed ID: 28567671
[TBL] [Abstract][Full Text] [Related]
11. An evaluation of RVX-208 for the treatment of atherosclerosis.
Nikolic D; Rizzo M; Mikhailidis DP; Wong NC; Banach M
Expert Opin Investig Drugs; 2015; 24(10):1389-98. PubMed ID: 26364508
[TBL] [Abstract][Full Text] [Related]
12. RVX-208, a stimulator of apolipoprotein AI gene expression for the treatment of cardiovascular diseases.
McNeill E
Curr Opin Investig Drugs; 2010 Mar; 11(3):357-64. PubMed ID: 20178050
[TBL] [Abstract][Full Text] [Related]
13. A novel compound 4010B-30 upregulates apolipoprotein A-I gene expression through activation of PPARĪ³ in HepG2 cells.
Du Y; Wang L; Si S; Yang Y; Hong B
Atherosclerosis; 2015 Apr; 239(2):589-98. PubMed ID: 25734982
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of HDL-modulating interventions for cardiovascular risk reduction using a systems pharmacology approach.
Gadkar K; Lu J; Sahasranaman S; Davis J; Mazer NA; Ramanujan S
J Lipid Res; 2016 Jan; 57(1):46-55. PubMed ID: 26522778
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial.
Nicholls SJ; Gordon A; Johansson J; Wolski K; Ballantyne CM; Kastelein JJ; Taylor A; Borgman M; Nissen SE
J Am Coll Cardiol; 2011 Mar; 57(9):1111-9. PubMed ID: 21255957
[TBL] [Abstract][Full Text] [Related]
16. Corrigendum to "RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease" [Atherosclerosis 247 (2016) 48-57].
Gilham D; Wasiak S; Tsujikawa LM; Halliday C; Norek K; Patel RG; Kulikowski E; Johansson J; Sweeney M; Wong NC
Atherosclerosis; 2016 Oct; 253():345. PubMed ID: 27211480
[No Abstract] [Full Text] [Related]
17. Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism.
Tsujikawa LM; Fu L; Das S; Halliday C; Rakai BD; Stotz SC; Sarsons CD; Gilham D; Daze E; Wasiak S; Studer D; Rinker KD; Sweeney M; Johansson JO; Wong NCW; Kulikowski E
Clin Epigenetics; 2019 Jul; 11(1):102. PubMed ID: 31300040
[TBL] [Abstract][Full Text] [Related]
18. HDL-Targeting Therapeutics: Past, Present and Future.
Zakiev E; Feng M; Sukhorukov V; Kontush A
Curr Pharm Des; 2017; 23(8):1207-1215. PubMed ID: 27799042
[TBL] [Abstract][Full Text] [Related]
19. How Might Bromodomain and Extra-Terminal (BET) Inhibitors Operate in Cardiovascular Disease?
Schooling CM; Zhao JV
Am J Cardiovasc Drugs; 2019 Apr; 19(2):107-111. PubMed ID: 30693439
[TBL] [Abstract][Full Text] [Related]
20. Selective BET Protein Inhibition with Apabetalone and Cardiovascular Events: A Pooled Analysis of Trials in Patients with Coronary Artery Disease.
Nicholls SJ; Ray KK; Johansson JO; Gordon A; Sweeney M; Halliday C; Kulikowski E; Wong N; Kim SW; Schwartz GG
Am J Cardiovasc Drugs; 2018 Apr; 18(2):109-115. PubMed ID: 29027131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
